Business Wire

Chugai's HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A Without Inhibitors

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The FDA has also approved additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors. The US application was submitted by Genentech, a member of Roche Group.

“We are very pleased that HEMLIBRA has obtained its first regulatory approval for people with hemophilia A without inhibitors,” said Chugai’s President & CEO, Tatsuro Kosaka. “Now people with hemophilia A in the US can be offered flexibility in HEMLIBRA’s dosing interval from multiple options depending on their needs, regardless of their inhibitor expression. We anticipate that HEMLIBRA will make an even greater contribution to the advancement of treatment of hemophilia A.”

This regulatory approval is based on results from two Phase lll studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of HEMLIBRA subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of HEMLIBRA subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.

HEMLIBRA was granted Priority Review and Breakthrough Therapy Designation by the FDA in hemophilia A without inhibitors, following the prior designations in hemophilia A with inhibitors. Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. In Japan and the EU, applications have been filed to regulatory authorities and are currently under review for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Trademarks used or mentioned in this release are protected by law.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

C3.ai Named a Leader in Worldwide Industrial IoT Platforms for Energy by IDC MarketScape20.6.2019 21:16:00 CESTPressemelding

C3.ai, a leading enterprise AI software provider for accelerating digital transformation, today announced it has been named a leader in IIoT platforms within the energy sector according to the IDC Marketscape: Worldwide Industrial IoT Platforms in Energy 2019 Vendor Assessment (IDC #US45116919, June 2019). C3.ai delivers a software suite for rapidly developing, deploying, and operating large scale AI, predictive analytics, and IoT applications for any enterprise value chain in any industry, with a focus on industrial organizations. C3.ai software enables leading organizations to rapidly design, develop, deploy, and operate enterprise-scale AI, predictive analytics, and IoT applications. C3.ai’s growing list of customers includes 3M, Shell, Enel, New York Power Authority, the United States Air Force, Con Edison, and ENGIE. The IDC MarketScape cited customer feedback that “C3 enables customers to build models and deploy applications in less time with limited risk. These tools have enable

Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator20.6.2019 20:01:00 CESTPressemelding

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “Ultrasound is becoming increasingly important in diagnosing breast cancer, and we believe SuperSonic Imagine offers superior technology that translates into better clinical outcomes for breast cancer patients, as well as for patients with liver and prostate disease.” Under the terms of

Digital Transformation Gets Bigger, Better, Bolder at LiveWorx’1920.6.2019 17:54:00 CESTPressemelding

A record crowd gathered in Boston last week for the annual LiveWorx® digital transformation event, where attendees explored how digital transformation is becoming a reality for an ever-increasing number of manufacturing companies around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190620005610/en/ The annual LiveWorx event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) with content spanning disruptive technologies including AR, IIoT, Industry 4.0 and more. LiveWorx 2020 will take place between June 8-11 in Boston's Innovation District. The event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) for four days of interactive workshops, facilitated industry networking, cutting-edge demos featuring the latest enter

INSERTING and REPLACING Arch Capital Group Names Seamus Fearon EVP, Credit Risk Transfer and Services, Global Mortgage Group20.6.2019 16:47:00 CESTPressemelding

Insert at end of first sentence of release: subject to regulatory approval. The corrected release reads: ARCH CAPITAL GROUP NAMES SEAMUS FEARON EVP, CREDIT RISK TRANSFER AND SERVICES, GLOBAL MORTGAGE GROUP Arch Capital Group Ltd. (Arch) today announced that Seamus Fearon has been promoted to Executive Vice President, Credit Risk Transfer and Services, Global Mortgage Group, subject to regulatory approval. In this role, Fearon will have responsibility for managing Arch’s credit risk transfer (CRT) business and growing its credit risk services offerings. He most recently was Chief Actuary of Arch’s Global Mortgage Group, where he oversaw its capital management framework and the development of its analytics and modeling capabilities. This newly created role highlights Arch’s focus on participating in credit risk transfer programs and supporting customers who would like to enter that growing market. “As the mortgage insurance market in the U.S. becomes even more competitive, it’s important

The “Centre Hospitalier de la Côte Basque” in France Has Started the Evaluation of the Biolog-id’s C-LOG® Solution20.6.2019 15:35:00 CESTPressemelding

The Centre Hospitalier de la Côte Basque (CHCB) in Bayonne has been using Biolog-id's C-LOG® solution since early April 2019. This solution secures and optimizes the circuit of chemotherapy and immunotherapy, from their preparation all the way to the administration to the patient. The C-LOG® solution has been used at the CHCB. "During the last HAS audit, a lack of traceability was revealed in the chemotherapy circuit. In order to close this gap, we decided to install the C-LOG® solution which, in addition to securing the administration to the patient's bed, makes it possible to trace the preparation circuit from the pharmacy to the reception in the nurses station," says Dr. Burtin, Pharmacist at CHCB. The solution will be tested for evaluation for 3 months before final adoption. "The RFID (Radio Frequency Identification) technology is the foundation of our solution. The tag affixed on each preparation contains the product and patient data. This information is updated in real-time and c

CSC Announces Cyber Security Findings for the Media Industry20.6.2019 15:00:00 CESTPressemelding

Securing a company’s digital infrastructure has become a major concern to corporations worldwide. With leading security companies and other organizations alerting corporations and the public to recent widespread, state-sponsored domain name system (DNS) hijacking, more and more brands are starting to take action. CSC has been issuing Cyber Security Reports since 2017, culling the most important information about security risks, and in particular, risks to brands that are not mitigated by a traditional firewall. The recent research conducted by CSC focuses on the media industry, revealing that 78% of global media brands use a corporate domain registrar, yet only 37% of those have a registrar lock to protect their DNS from hijacking. Recent domain hijacking, unauthorized changes, and deletion of vital domains have shown that effectively managing domain names and DNS must become a critical component for enhancing the security posture of any company with an online presence. More worrisome